BCL2L1 and B-cell acute lymphoblastic leukemia: Interestingly, an shRNA drug screen previously identified Bcl‐xL as a target for combination therapy with MEKi in different cancer models [42], and high expression of Bcl‐xL is associated with resistance to chemotherapy in B‐cell acute lymphoblastic leukemia (B‐ALL) [43].